Pharma Pulse 7/31/25: Where Has AI Already Been Successfully Implemented; How Biomarkers Are Transforming Neurology and Oncology Trials

Where Has AI Already Been Successfully Implemented?

In an interview with Pharmaceutical Executive, Gen Li, president and founder of Phesi, discussed how AI has already been successfully implemented in partnership with several top pharmaceutical companies to improve clinical trial design, patient recruitment, and site performance—particularly through the use of digital patient profiles—while also highlighting its future potential to replace control arms using digital twins.

How Biomarkers Are Transforming Neurology and Oncology Trials

In an interview with Applied Clinical Trials, Michael Miller, chief operation officer of Quanterix, explained how biomarkers are transforming clinical trials in neurology—through advances like blood-based diagnostics—and in oncology—via multiomic strategies and protein tissue imaging—helping improve patient selection, streamline trial efficiency, and accelerate drug development.

Pharmacists' Guide to Selection and Use of At-Home Blood Pressure Monitors

At-home blood pressure monitoring plays a critical role in managing hypertension, and pharmacists are uniquely positioned to guide patients in selecting validated devices, ensuring proper measurement technique, and supporting long-term adherence to treatment and lifestyle changes.

MD Anderson and TOPPAN Holdings Announce Strategic Alliance to Co-Develop Organoid Technology for Evaluating Cancer Treatments

MD Anderson Cancer Center and TOPPAN Holdings have formed a strategic alliance to co-develop and clinically validate TOPPAN’s invivoid 3D organoid technology as a personalized cancer treatment tool, with plans to seek CAP/CLIA certification and usepatient-derived samples to predict therapy responses and improve treatment outcomes.

The Impact of Valproic Acid on Neonatal Outcomes

Valproic acid use during pregnancy is strongly associated with significant risks—including congenital malformations, growth restriction, and neurodevelopmental disorders such as intellectual disability, autism spectrum disorder, and ADHD—necessitating careful risk-benefit assessment, while postnatal exposure through breastfeeding appears minimal and generally safe.